Skip to main content
PLOS One logoLink to PLOS One
. 2021 Feb 26;16(2):e0247951. doi: 10.1371/journal.pone.0247951

Understanding the impact of the SARS-COV-2 pandemic on hospitalized patients with substance use disorder

Caroline King 1,2,*, Taylor Vega 2, Dana Button 2, Christina Nicolaidis 1,3, Jessica Gregg 1,4, Honora Englander 1
Editor: Cynthia Sieck5
PMCID: PMC7909702  PMID: 33635926

Abstract

Background

The SARS-COV-2 pandemic rapidly shifted dynamics around hospitalization for many communities. This study aimed to evaluate how the pandemic altered the experience of healthcare, acute illness, and care transitions among hospitalized patients with substance use disorder (SUD).

Methods

We performed a qualitative study at an academic medical center in Portland, Oregon, in Spring 2020. We conducted semi-structured interviews, and conducted a thematic analysis, using an inductive approach, at a semantic level.

Results

We enrolled 27 participants, and identified four main themes: 1) shuttered community resources threatened patients’ basic survival adaptations; 2) changes in outpatient care increased reliance on hospitals as safety nets; 3) hospital policy changes made staying in the hospital harder than usual; and, 4) care transitions out of the hospital were highly uncertain.

Discussion

Hospitalized adults with SUD were further marginalized during the SARS-COV-2 pandemic. Systems must address the needs of marginalized patients in future disruptive events.

Introduction

The SARS-COV-2 pandemic has profoundly impacted communities around the globe. Marginalized communities, where people are excluded from full economic, sociopolitical, and cultural participation [1, 2], have disproportionately borne the harms of the pandemic [37]. People with substance use disorder (SUD) experience marginalization in many social systems [810], including in healthcare [1113]. Historically, this has manifested as healthcare systems that, at best, fail to adapt to function in the ways people with SUDs need to thrive [14], and at worst, actively drive participants from care through stigmatizing and discriminatory encounters [10].

Hospitalization may be a particularly challenging time for people with SUDs, as they commonly experience untreated withdrawal and pain and work to mitigate hospital-based social control (e.g. the rules and regulations that dictate acceptable behavior in hospitals) [15]. Negative and stigmatizing experiences during hospitalization can lead patients with SUDs to avoid presenting to the hospital until illnesses are dire, leave the hospital against medical advice, and trust healthcare providers less than patients without SUDs [1518]. Avoiding healthcare systems, or leaving the hospital without completing recommended therapy, carries increased risk during a pandemic [19]. However, hospitals are also in a unique position to support patients with SUD, by providing evidence-based, compassionate care, including harm reduction tools, and by improving systems to meet the needs of people with SUD [20, 21].

The SARS-COV-2 pandemic rapidly and dramatically shifted care dynamics before, during, and after hospitalization for many communities. To help prevent the spread of SARS-COV-2 hospitals enacted many changes, including limiting visitors and reducing or eliminating in-person visits between providers and patients [2224]. The SARS-COV-2 pandemic and mitigation strategies may have uniquely impacted people with acute illness and SUD. As we assess the ways in which hospitals’ responses to the pandemic have succeeded and failed, we must include voices of people at the margins, and specifically, voices of people with SUD. By conducting qualitative research directly with people who are marginalized, we can understand how hospital policy changes have impacted them, which can help healthcare systems learn how to better care for patients in the future. Their experiences can highlight unique opportunities and gaps that can inform usual hospital care, as well as ongoing and future emergency responses. This study aimed to evaluate how the SARS-COV-2 pandemic has altered the experience of healthcare, acute illness, and care transitions among hospitalized patients with substance use disorder.

Methods

Setting and study design

We performed a qualitative study at an urban academic medical center in Portland, Oregon. This hospital is a 576-bed Level 1 Trauma Center located on the top of a hill in the city [25]. OHSU sees a wide variety of patients for acute medical and surgical illness, and often receives transfers of patients from smaller hospitals across Oregon. In this study, all participants saw an inpatient addiction medicine consult service called the Improving Addiction Care Team (IMPACT). IMPACT is the only inpatient addiction medicine consult service in the state of Oregon, though some other hospitals provide medication for Opioid Use Disorder in inpatient settings. IMPACT cares for adults with SUD, including but not limited to opioids, alcohol, and methamphetamines. The team includes addiction medicine providers, social workers, and peers with lived experienced in recovery. Earlier work describes IMPACT development, intervention, and outcomes [2629].

COVID-19 related changes and data collection timeline

OHSU implemented COVID-19 modified operations on March 23, 2020. Initially, the hospital restricted all patient visitors and encouraged clinicians who could to tele-work to preserve personal protective equipment (PPE) and support physical distancing [30]. For the first month of modified operations, IMPACT medical providers predominantly consulted via telephone, reserving rare in-person visits for patients with cognitive issues, severe unmanaged withdrawal, or inability to participate in telephone visits. IMPACT social workers maintained some in-person hours but shifted primarily to telephone, and peers worked exclusively by phone. Despite best efforts, IMPACT could not perform patient visits via video, as most patients lacked smartphones and hospital rooms were not equipped with video technology. IMPACT leadership tried to secure personal electronic devices (e.g. smartphones, tablets) for patients to support video communication, but issues of cost and competing priorities were barriers and efforts did not come to fruition until after the study window. Researchers conducted individual telephone interviews between April 15 and May 29, 2020. Starting in mid-April of 2020, as hospital PPE was more available–and because of limitations of telephone-based care–medical providers transitioned back to in-person visits. In May, peer mentors resumed in-person visits. Social workers continued alternating telephone and in-person work due to the need for physical-distancing in office spaces. Overall, IMPACT returned to in-person operations sooner than many hospital services. Oregon and Portland have had low rates of cases of SARS-COV-2 and fatalities compared to states and cities nationally. As of late September 2020, Oregon reported 730 cases of COVID-19 per 100,000 people to the CDC, the second lowest of six rate-groups in the United States [31].

Participants and data collection

Our institutional IRB waived the requirement for written consent given the inability to meet patients in person because of university-wide restrictions, and because of the minimal risk associated with our study. To recruit patients, we called the rooms of hospitalized patients with SUDs who were referred to IMPACT. We ascertained patient interest in learning about the study, and verbally consented patients to participate. Patients were offered $25 gift cards to thank them for participating.

For the quantitative survey, we included nine demographics questions and ten questions from the Brief Addiction Monitor [32]. The Brief Addiction Monitor has previously been used in inpatient settings with patients with substance use disorders [33, 34]. We also assessed participant readiness-to-change by substance, using four questions our team uses in research to assess substance use (“Please describe how you feel about your alcohol/opioid/amphetamine or methamphetamine/other drug use right now: 1) I do not want to think about cutting back or quitting, 2) I want to cut back but I am not ready to quit, 3) I want to quit, and 4) I quit before I was admitted to the hospital”). We developed the last question because we have been unable to find a measure that adequately measures readiness to change, by substance, for patients hospitalized with substance use disorders. We piloted tested the full survey among research team members prior to the start of the research project.

Semi-structured interviews explored participants’ social networks; social services access; substance use, harm reduction, and treatment; housing; and experiences with medical care during the SARS-COV-2 pandemic (S1 File). Typically, interviews lasted 20–45 minutes.

The interview team consisted of three medical students, two female and one male, all interested in addiction medicine. Prior to the start of the study, two researchers who are experts in qualitative researcher (CN, HE) reviewed qualitative research steps for conducting interviews with the three medical students (CK, TV, DB), and oversaw the project for its duration. Then, one student with more qualitative experience (TV) conducted a mock interview with a student with less qualitative experience (DB) and gave feedback as to how to elicit rich qualitative data. Each of the three interviewers then did an initial one to two interviews. These interview recordings were transcribed, and the full research team reviewed transcripts and provided feedback on interviewing techniques. Researchers securely recorded interviews via Webex and interviews were transcribed verbatim (Landmark Transcription Services).

Data analysis

We conducted a thematic analysis, using an inductive approach, at a semantic level (e.g. where interview data were taken at face value) [35, 36]. The research team (CK, TV, DB, HE) reviewed five transcripts and generated initial codes. Three researchers (CK, TV, DB) then used an iterative approach to apply codes to all transcripts and update the codebook. All interviews were coded by at least two researchers, who met to regularly reconcile codes. The full team reviewed codes and identified preliminary themes, using a subjective heuristic for determining significance. A significant theme needed to: 1) be expressed by multiple participants; 2) be expressed as a central concern, 3) describe patient experiences related to acute illness or SUD, and the SARS-COV-2 pandemic. Researchers then re-reviewed primary data, chose representative quotations, and finalized themes. We used Dedoose [37] to manage qualitative data.

We used descriptive statistics to describe participant characteristics. We used Stata 16 [38] for quantitative analyses.

The Oregon Health & Science University Institutional Review Board approved this study (IRB #21399).

Results

Participant characteristics

We approached 42 patients via telephone to participate, and enrolled 27 participants. Of the 15 patients who declined to enroll, 8 said that they were not interested, 2 were managing acute illness and did not want to be on the phone, and 5 did not provide a reason for not participating. Of those who enrolled, most were male (59.2%), White (81.4%), and had a regular source of primary care (74.1%). Participants most commonly had opioid use disorder (OUD) (59.3%), methamphetamine use disorder (MethUD) (40.7%), or alcohol use disorder (AUD) (40.7%) (Table 1). Nearly three-quarters of participants (74.1%) stated that they did not have enough money to pay for basic necessities like food and clothing, and nearly half did not have a cell phone (48.1%).

Table 1. Participant demographics.

Variable Study participants N (%) or Avg (SD)
Age (years) 48.9 (11.5)
Gender (Male) 16 (59.2%)
Race
White 22 (81.4%)
Black 1 (3.7%)
American Indian/Alaska Native 5 (18.5%)
More than one race 1 (3.7%)
Refused 1 (3.7%)
Hispanic 1 (3.7%)
High-school education 23 (85.2%)
Currently homeless 10 (37.0%)
Have enough income to pay for necessities in past 30 days 7 (25.9%)
Have a cell phone 14 (51.9%)
Usual place of primary care 20 (74.1%)
SUD Diagnoses
Opioid Use Disorder 16 (59.3%)
Methamphetamine Use Disorder 11 (40.7%)
Cocaine Use Disorder 3 (11.1%)
Alcohol Use Disorder 11 (40.7%)
Benzodiazepine Use Disorder 2 (7.4%)
Other Use Disorder 4 (14.8%)
Attended self-help meeting in past 30 days 2 (7.4%)
Bothered by cravings in past 30 days (n = 26)
Not at all 10 (38.5%)
Slightly 1 (3.8%)
Moderately 2 (7.7%)
Considerably 0
Extremely 13 (50.0%)

Most participants reported that their substance use changed during the pandemic. In qualitative data, nearly everyone who used alcohol noted that their alcohol consumption increased during the pandemic. In contrast, participants who used methamphetamine described using less methamphetamine because of rapidly increasing costs and decreasing quality, while participants using heroin or other opioids noted use did not change or increased.

In qualitative analysis, we identified four themes and ten subthemes (in italics) related to acute illness, system stability and care transitions (Table 2). The shuttering of community resources threatened patients’ basic survival adaptations before admissions. Additionally, changes in outpatient care increased reliance on hospitals as safety nets. Once hospitalized, hospital policy changes made it harder to stay, and care transitions out of the hospital were more uncertain than before the pandemic. We describe these below.

Table 2. Qualitative themes and subthemes.

Theme Subtheme
Shuttering of community resources threatened patient’s basic survival adaptations before admission Intensified insecurity around basic needs
Heightened toll of homelessness
Virtual meetings limited engagement and access to outpatient substance use services
Changes in outpatient care increased reliance on hospitals as safety nets Lack of technology severely limited access to the outpatient care that remained open
Participants turned to the hospital when they were sick, particularly if they did not own a phone
Changes in hospital policy made receiving care and staying in the hospital harder than usual. Hospitalization was more isolating than ever
PPE solidified the gravity of the pandemic and signaled strict rule-enforcement
Inpatient addiction care was essential during the pandemic
Transitions out of hospital care were highly uncertain Housing was a top worry post-discharge
Participants worried about new and ongoing vulnerabilities following acute illness

First, the shuttering of community resources threatened patient’s basic survival adaptations before admission. During the SARS-COV-2 pandemic, participants reported intensified insecurity around basic needs, including accessing food, employment, housing, social services, and hygiene facilities. Each system that participants described was harder to access either because of increased demand (food), or because participants could not reach offices virtually, physical offices were closed, or both (social services, hygiene facilities).

For participants without housing, the pandemic heightened the toll of homelessness. Some participants perceived increased stigma associated with homelessness during the pandemic, noting that others were less willing to engage with them for fear of contracting SARS-COV-2. Restaurants and stores were closed, eliminating options to warm-up, sleep, access Wi-Fi, or panhandle outside. One participant, who was homeless and admitted with heart failure, shared that he and his wife struggled now that the physical McDonald’s location was closed:

“We’d get up in the morning and go over to McDonald’s and get the dollar coffee and sit there, and surf the web on your phone. It was all it was. Following the COVID-19—what was gonna happen next? Now they’re gonna close this, they’re gonna close that, oh, crap. Now you can’t do anything except through the drive-through. We just watched it tumble down.” (Participant 14).

Some participants became newly homeless or housing-unstable because of arguments and strained relationships in the context of the pandemic. Some participants left romantic partners, family or friends to live outside, while others moved between different homes. Participants who shifted to living outside described having nowhere else to turn during the pandemic.

Next, a shift to virtual meetings limited engagement and access to outpatient substance use services. Many support group meetings (e.g. Narcotics Anonymous) moved online or stopped altogether during the pandemic. This led some participants to return to substance use, and others to increase use. The shift online was particularly harmful to people who lacked smartphones or internet. One participant, who predominately used opioids and benzodiazepines and did not own a phone, described being “depressed” and noted that an inability to access recovery meetings “made my use go up because I felt lost.” (Participant 17). Importantly, participants reported how syringe distributions sites responded differently to the pandemic: they largely remained open, they promoted physical distancing, and offered more supplies to reduce the number of trips people had to make. Participants found harm reduction services to be an “actually helpful” system in unstable times.

Some patients felt that these acute changes in society, and the subsequent changes in their substance use, contributed, or led, to their hospitalization. For others, personal struggles to survive during the pandemic added additional layers of complexity to hospitalization and post-discharge plans.

Second, we found that changes in outpatient care increased reliance on hospitals as safety nets. Just as not having a phone excluded patients from virtual recovery meetings, it also severely limited access to the outpatient care that remained open. Without a phone or other electronic device, participants reported that they could not contact outpatient providers to make appointments or seek guidance. Participants described that societal shifts to communicating via technology “threw a wrench in the works” during the pandemic. Some participants blamed outpatient care facilities that were not allowing in-person visits. One participant with no phone described,

“I’ve had hellacious problems…. Before I came to the hospital, I couldn’t get a doctor’s appointment for the life of me to get that port out of my chest…I’m pretty sure that’s what put the clot in my heart, you know?” (Participant 17).

Another participant expressed worry that shuttered outpatient care had delayed his access to a diagnostic colonoscopy and made him sicker, eventually landing him in the hospital.

“They bumped [the colonoscopy] and said they’d get a hold of me when they were doing them again. Then, they finally got a hold of me, and by then I was really sick…. Just I hope it’s not too late.” (Participant 24).

While not having a phone was a unique stress for participants trying to access outpatient services, even participants with phones described challenges accessing care. Some participants who contacted their primary care office for a medical issue felt that in pre-COVID times, their primary care provider would have seen them in-office, but because of the pandemic and because they were very sick, they were sent to the emergency department instead.

When outpatient care was open only for virtual visits, participants turned to the hospital when they were sick, particularly if they did not own a phone. Participants saw this as a last resort, and described worries of contracting SARS-COV-2 and being separated from family and friends during such a vulnerable time of acute illness. One participant, admitted with MRSA bacteremia and cellulitis, described presenting to the hospital emergency department, when her friend and partner were unable to accompany her:

“I was afraid to come in at all and really wanted and needed them with me, that support….I made it as far as the outside doors to the emergency department. They had those COVID like tents set up… I just burst into tears and turned around…. I just kept walking and went to a bus stop and went home. I was afraid to go in and I didn’t….I chickened out the first time and was afraid to go in, so not being able to have somebody with me really affected me. I had to work up the courage to do it all by myself.” (Participant 19).

Participants saw hospitalization as a last, essential resort, and often tried to avoid it by attempting to seek care elsewhere or delaying their presentation to care. Because care elsewhere was often inaccessible, particularly to participants without phones or internet, there was increased reliance on hospitals as safety nets during the early months of the SARS-COV-2 pandemic.

Changes in hospital policy made receiving care and staying in the hospital harder than usual

For most participants, care teams would call patient rooms instead of visiting in person, if possible. While a few participants found this helpful, most felt it was difficult, and that receiving constant phone calls to their room was exhausting and made building trust with providers difficult. As one participant, who primarily used methamphetamine and opioids, shared,

“I much prefer [seeing providers] in-person. The over-the-phone…it’s a little bit more cold and impersonal…you’ve never met before, you’ve never shook hands, you’ve never laid eyes on each other… There’s something about meeting a person, and looking them in the eyes, and shaking their hand that I realize for me really means a lot. I can’t just open up to somebody that I just talked to on the phone in the same way.” (Participant 16).

Additionally, participants who had previously been hospitalized noted that hospitalization was more isolating than ever before for two reasons. First, participants had no in-person family and social support, due to restricted visitor polices aimed at preventing the spread of SARS-COV-2. Second the transition to telemedicine resulted in decreased interactions with healthcare providers, compounding widespread feelings of “isolation” in the hospital. One participant with alcohol use disorder shared,

“It’s lonely…I have my cellphone, but I can’t have visitors. There’s hardly any nurses and doctors in the hallways. You really don’t see anybody. Everybody’s locked away.” (Participant 23)

Simultaneously, when providers did enter participant rooms, they donned PPE. Participants found PPE to be both comforting, in that they expected providers to be wearing it, and anxiety-inducing, because watching providers don PPE solidified the gravity of the pandemic and signaled strict rule-enforcement. One participant, with opioid use disorder, noted:

“They’re very strict on their procedures that they put in place for the virus… I don’t blame anybody for that. They’re trying to do the right thing. God forbid. I just hope this whole thing is over with sometime soon.” (Participant 27).

Participants noted that inpatient addiction care was essential during the pandemic, and increasingly so as some participants newly returned to substance use. One participant shared that he felt IMPACT was

“… very essential at this point in time, because I feel that I’m not the only person that’s turning to drugs and alcohol…. I like the fact that [IMPACT] are there. I can call them. They’ll come see me. They can talk to me about anything. I can talk to them about anything.” (Participant 16).

As the pandemic progressed, IMPACT shifted from telemedicine to mostly in-person visits. For some participants, phone visits with IMPACT did not work. As one participant who was scared to present to the hospital because of SARS-COV-2 risk described, “…they were just voices on the phone. I [couldn’t] even keep them straight, who was who, the name with the—I didn’t know from one call to the next really.” (Participant 19). Others noted how much they appreciated the in-person visits from IMPACT, describing “… I appreciate[d] the fact that you’re not scared of the coronavirus to actually come and see me in my hospital room.” (Participant 16).

Participants described inpatient addiction care as essential during hospitalization during the SARS-COV-2 pandemic, and highlighted the importance of in-person communication to build trust with addiction providers.

Finally, for study participants, transitions out of hospital care were highly uncertain. For nearly every participant, housing was a top worry post-discharge. Participants worried about new and ongoing vulnerabilities following acute illness. One participant with opioid use disorder, who lost his housing just before admission and was admitted for infection and frostbite, described:

“Even when I get out of here, I can’t go back out on the streets and be like the status that I’m in right now. It just won’t work …I’ll be an open target. … They’ll come take all your medications from you. They’ll steal everything you own…. You got to fall asleep sometime.” (Participant 27).

SARS-COV-2 heightened risks of these already vulnerable transitions, introducing uncertainty into where people could go, who they would be around, how they would limit risks for SARS-COV-2 infection, and because of the challenges they would face meeting basic survival needs. One participant noted,

“My biggest concern when I leave the hospital is relocating to a place where I know really not many people and where I can pick and choose the crowd that I allow myself to be surrounded by. My biggest concern is finding some type of safe, secure place that I could lay my head because I’m gonna have a lot of open tubes.” (Participant 16).

Many participants described added uncertainty of how they would manage their health conditions, and other unknown post-discharge dynamics. Participants shared the experience of having few answers and many fears about the post-discharge period.

Discussion

Our study describes the ways in which SARS-COV-2 has impacted the lives of hospitalized patients with SUD. Most participants reported increased marginalization because of policy changes. They reported the shuttering of community resources threatened their survival strategies, intensifying insecurity around basic needs and amplifying the toll of being homeless. Changes in outpatient care increased reliance on hospitals as safety nets. Having a phone and internet were essential to accessing outpatient care virtually, and in the absence of these, participants reported turning to the hospital when they were sick. Once admitted, changes in hospital policy made staying in the hospital harder than usual. Participants found the hospital isolating and had difficultly connecting with providers by phone. Participants described addiction care as essential during this time. Finally, discharge care transitions were even more uncertain than before the pandemic. Housing was a top concern, and participants worried about worsening challenges facing recovery from acute illness following discharge.

Our results map onto the large body of work that describes people who are marginalized, including people with addiction, as rarely considered before disaster strikes, and thus disproportionately impacted by disruptive events like pandemics and natural disasters [3945]. Most research around addiction in the face of disruptive events has focused on challenges in rapidly shifting treatment systems (e.g. reintegrating those fleeing Hurricane Katrina into methadone clinics in Texas [45]; shifting buprenorphine prescribing to a different clinic following hospital flooding in New York [40]), in which treatment systems must quickly adapt to minimize interruptions in medication-based treatment. Participants in our study did not describe challenges accessing buprenorphine or methadone, but did describe challenges accessing addiction care like outpatient recovery meetings. Published studies also highlight increased substance use among people already using substances after disruptive events [41]. Participants in our study endorsed this trend, highlighting that given increased isolation and anxiety during the pandemic, substance use often increased for participants using alcohol and, sometimes, opioids.

However, outside of the context of treatment interruptions, little research has described the impact of disruptive events on the lives of people who use drugs. Participants in our study described that policy changes created threats to survival (increased homelessness, decreased access to outpatient care) before hospitalization with acute illness. Participants recognized they were returning to these same dynamics after discharge, and often wondered how they would manage illness in the face of compounding vulnerabilities. Care transitions, a vulnerable time for patients with substance use disorder in non-pandemic times [46, 47], were fraught with heightened uncertainty and worry. Participant experiences of system-failures highlighted that decision-makers within healthcare and government were unprepared to rapidly adjust to the needs of patients with SUD, particularly for patients who were also homeless.

As marginalization is driven by the socio-political and economic contexts of society [48], it is unsurprising that systems that permit marginalization were not prepared to respond to the SARS-COV-2 pandemic in the ways necessary to protect patients with addiction from harm. Importantly, however, two systems were prepared to mitigate suffering for patients with addiction. First, outside of the hospital, needle exchange services rapidly adapted to allow people to both decrease the risk of SARS-COV-2 transmission and access safer-injection supplies. Second, within the hospital, the addiction consult service continued to see patients with addiction and worked with study participants to mitigate heightened uncertainty and isolation in the face of the pandemic, particularly around transitions out of the hospital. Both findings build on existing literature that show addiction consult services, in non-pandemic times, help build trusting patient-provider relationships [17], improve engagement in substance use treatment after hospital discharge [26], and help patients determine and pursue their healthcare goals [18, 27]. Participants described addiction consult services as especially important during the pandemic. Both addiction consult services and needle exchange services incorporate voices of people with lived experience with SUD from the earliest stages of planning [29, 49]. This natural programmatic inclination to seek and incorporate the needs of people with SUDs in non-pandemic times may have facilitated rapid responsiveness to the needs and goals of people with SUD during the SARS-COV-2 pandemic.

Our study has several limitations. First, we conducted our study at a single, academic medical center, which may limit generalizability, as community-based hospitals may see different challenges among patients with substance use disorders admitted to the hospital. Second, Oregon had relatively low rates of SARS-COV-2 infections during the study period, but this has since changed [31]. It is possible that patient experiences and priorities differ depending on community prevalence of SARS-COV-2; however, the strains imposed by shuttered services, hospital policies, and high-risk transitions would likely only be further compounded in settings with high SARS-COV-2 cases (for example, in Philadelphia, where treatment clinics did close [50]). Third, our sample had low racial and ethnic diversity. Because Black, Indigenous, and People of Color disproportionately suffered from death and other complications of SARS-COV-2 [51] and also disproportionately experience opioid-related harms, including during the pandemic [52], future work should explore intersecting vulnerabilities of SUD, hospitalization, and acute crises like pandemics in this population. Fourth, it is possible that our research does not encompass all challenges faced by marginalized patients in healthcare systems. While we focus specifically on patients with substance use disorders and highlight that addressing challenges for these patients may benefit other marginalized groups, there may be other, unique, challenges that should be explored through further research with other marginalized patient populations. Fifth, as is common in emergencies, policy within the hospital related to COVID-19 rapidly changed over the study period. We do not know to what degree these rapid changes may have impacted study results. Sixth, additional research is needed to understand how the SARS-COV-2 pandemic directly impacted substance use access, practices, and use. While we found differences in use practices and access by primary substance, this question is better answered using quantitative data.

Our findings have important implication for hospital providers, health systems, and policy makers. Hospital providers may need to reconsider what constitutes readiness for discharge during future disruptive events, and consider factors like access to technology, shelter, and ambulatory care–all of which were disrupted for participants in our study. Further, it is important for hospital providers to understand patient’s intensified feelings of isolation, and the challenges to building trusting relationships with structural barriers, including virtual visits and PPE. To address this, providers may empathize with patient’s circumstances, offer extra compassion or small gestures to connect with patients, and inquire as to how they can support patients during stressful times. Chua et al. [23] have derived guidelines for serious illness conversations held virtually in palliative care settings during the pandemic; aspects of these guidelines may be useful for working with any vulnerable population, and include acquainting the patient to the technology and responding to patient emotion.

In the face of outpatient closures, increasing disease and injury, or both, healthcare systems serve as a safety net for those with no place else to turn. Healthcare systems must be prepared for this role, not only for the general population, but also for patients who experience high degrees of marginalization, including patients with addiction. To do this, healthcare systems must incorporate the voices of marginalized people into disaster planning. In our study, nearly half of participants did not own a phone. Healthcare system shifts to telemedicine and virtual recovery supports were suddenly inaccessible to patients in need. Globally, shifts to telemedicine have impacted not only patients with substance use disorders, but also patients who are older, with disabilities, with lower socioeconomic status, and who are homeless [53]. First steps towards more equitable systems should identify basic barriers to health that could be relevant in most disasters, like technology access, access to shelter, clean water and food, and essential medicines, and work to address these challenges to support a basic level of health and wellness in communities. Mitigating these challenges in non-pandemic times can ease the burden of potential patient surges during crises, but marginalized communities must be involved in these decisions. Addiction consult services demonstrated the importance of this, as patients highlighted that addiction consult services helped meet their needs during their inpatient stay, particularly during the pandemic. As hospitals work to incorporate patient voices into policy planning, addiction consult services may serve as a cultural broker to help immediately care for vulnerable patients (particularly as they transition out of the hospital) and communicate important needs with hospital leadership, from patient perspectives.

Finally, as policy-makers prepare for future pandemics, natural disasters, or other disruptions, they must consider effects on marginalized populations, and specifically people with SUD, as a priority. To prevent future potential harms, policy-makers should help alleviate the need to simply survive in non-pandemic times and help support access to housing, harm reduction and treatment services. To do this, policy-makers must include marginalized people at the decision-making tables. In preparation for future events, hospital and other leaders must develop partnerships with organizations that understand community needs of marginalized people, including those with SUD, to anticipate and plan for diverse patient needs during times of crisis.

Conclusion

Hospitalized adults with SUD were further marginalized during the SARS-COV-2 pandemic. Hospitals providers and leaders play critical roles in creating systems that alleviate suffering and support people with SUD. To do this more effectively and in preparation for future disruptive events, healthcare systems must incorporate and amplify the voices of marginalized patients with SUD to alleviate suffering at the bedside and support safe transitions out of care. Responsive systems will be necessary to care for not only the masses, but the most marginalized, patients in the face of future disruptive events.

Supporting information

S1 File. Participant survey.

Survey for participants with substance use disorder, hospitalized during the SARS-COV-2 pandemic.

(PDF)

S1 Poster

(PPTX)

Acknowledgments

Prior presentations

Preliminary results from this work were presented as an abstract at AMERSA in Fall 2020.

Data Availability

We are unable to share data because data are potentially identifying and contain sensitive patient information. These restrictions are imposed by our ethics committee. Oregon Health & Science University’s Institutional Review Board can be contacted by emailing irb@ohsu.edu, or emailing Kathryn Schuff, Program Manager, at schuffk@ohsu.edu.

Funding Statement

CK and HE were supported by grants from the National Institutes of Health, National Institute on Drug Abuse (UG1DA015815/ R01DA037441). This publication was also made possible with support from the Oregon Clinical and Translational Research Institute (OCTRI), grant number UL1TR002369 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. CK was also supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Award Number TL1TR002371. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Baah FO, Teitelman AM, Riegel B. Marginalization: Conceptualizing patient vulnerabilities in the framework of social determinants of health-An integrative review. Nurs Inq. 2019. January;26(1):e12268. Epub 2018 Nov 29. 10.1111/nin.12268 ; PMCID: PMC6342665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Sharma M. Developing an integrated curriculum on the health of marginalized populations: successes, challenges, and next steps. J Health Care Poor Underserved. 2014. May;25(2):663–9. 10.1353/hpu.2014.0102 . [DOI] [PubMed] [Google Scholar]
  • 3.Laurencin CT, McClinton A. The COVID-19 Pandemic: a Call to Action to Identify and Address Racial and Ethnic Disparities. J Racial Ethn Health Disparities. 2020. June;7(3):398–402. Epub 2020 Apr 18. 10.1007/s40615-020-00756-0 ; PMCID: PMC7166096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Chenneville T, Gabbidon K, Hanson P, Holyfield C. The Impact of COVID-19 on HIV Treatment and Research: A Call to Action. Int J Environ Res Public Health. 2020. June 24;17(12):4548. 10.3390/ijerph17124548 ; PMCID: PMC7345635. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Melamed OC, Hauck TS, Buckley L, Selby P, Mulsant BH. COVID-19 and persons with substance use disorders: Inequities and mitigation strategies. Subst Abus. 2020;41(3):286–291. 10.1080/08897077.2020.1784363 . [DOI] [PubMed] [Google Scholar]
  • 6.D’cruz M, Banerjee D. ’An invisible human rights crisis’: The marginalization of older adults during the COVID-19 pandemic—An advocacy review. Psychiatry Res. 2020. October;292:113369. Epub 2020 Aug 3. 10.1016/j.psychres.2020.113369 ; PMCID: PMC7397988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Gates BG, M. COVID-19: A Global Perspective. 2020 Goalkeepers Report. Bill and Melinda Gates Foundation; 2020. 45 p.
  • 8.Draus PJ, Roddy JK, Greenwald M. A hell of a life: addiction and marginality in post-industrial Detroit. Soc Cult Geogr. 2010. November 1;11(7):663–680. 10.1080/14649365.2010.508564 ; PMCID: PMC4429794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Corrigan PW, Kuwabara SA., O’Shaughnessy J. The Public Stigma of Mental Illness and Drug Addiction: Findings from a Stratified Random Sample. Journal of Social Work. 2009;9(2):139–147. 10.1177/1468017308101818 [DOI] [Google Scholar]
  • 10.Richardson L, Wood E, Kerr T. The impact of social, structural and physical environmental factors on transitions into employment among people who inject drugs. Soc Sci Med. 2013. January;76(1):126–33. Epub 2012 Nov 2. 10.1016/j.socscimed.2012.10.015 ; PMCID: PMC3525755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Brondani MA, Alan R, Donnelly L. Stigma of addiction and mental illness in healthcare: The case of patients’ experiences in dental settings. PLoS One. 2017. May 22;12(5):e0177388. 10.1371/journal.pone.0177388 ; PMCID: PMC5439661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Lee SH, Petersen SR. Demarginalizing the marginalized in substance abuse treatment: Stories of homeless, active substance users in an urban harm reduction based drop-in center. Addiction Research & Theory. 2009;17(6):622–36. 10.3109/16066350802168613 [DOI] [Google Scholar]
  • 13.Luoma JB, Twohig MP, Waltz T, Hayes SC, Roget N, Padilla M, et al. An investigation of stigma in individuals receiving treatment for substance abuse. Addict Behav. 2007. July;32(7):1331–46. Epub 2006 Nov 7. 10.1016/j.addbeh.2006.09.008 . [DOI] [PubMed] [Google Scholar]
  • 14.McNeil R, Small W. ’Safer environment interventions’: a qualitative synthesis of the experiences and perceptions of people who inject drugs. Soc Sci Med. 2014. April;106:151–8. Epub 2014 Feb 4. 10.1016/j.socscimed.2014.01.051 ; PMCID: PMC4133147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.McNeil R, Small W, Wood E, Kerr T. Hospitals as a ’risk environment’: an ethno-epidemiological study of voluntary and involuntary discharge from hospital against medical advice among people who inject drugs. Soc Sci Med. 2014. March;105:59–66. Epub 2014 Jan 19. 10.1016/j.socscimed.2014.01.010 ; PMCID: PMC3951660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Lail P, Fairbairn N. Patients With Substance Use Disorders Leaving Against Medical Advice: Strategies for Improvement. J Addict Med. 2018. Nov-Dec;12(6):421–423. 10.1097/ADM.0000000000000432 ; PMCID: PMC6214759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.King C, Collins D, Patten A, Nicolaidis C, Englander H. Increased provider trust among participants with substance use disorder after consultation by a hospital-based addiction medicine consult service: an IMPACT study. Journal of Addiction Medicine. Under Review. [Google Scholar]
  • 18.Biancarelli DL, Biello KB, Childs E, Drainoni M, Salhaney P, Edeza A, et al. Strategies used by people who inject drugs to avoid stigma in healthcare settings. Drug Alcohol Depend. 2019. May 1;198:80–86. Epub 2019 Mar 8. 10.1016/j.drugalcdep.2019.01.037 ; PMCID: PMC6521691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Kimmel SD, Bazzi AR, Barocas JA. Integrating harm reduction and clinical care: Lessons from Covid-19 respite and recuperation facilities. J Subst Abuse Treat. 2020. November;118:108103. Epub 2020 Aug 12. 10.1016/j.jsat.2020.108103 ; PMCID: PMC7419278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Englander H, Patten A, Lockard R, Muller M, Gregg J. Spreading Addictions Care Across Oregon’s Rural and Community Hospitals: Mixed-Methods Evaluation of an Interprofessional Telementoring ECHO Program. J Gen Intern Med. 2020. September 3. Epub ahead of print. 10.1007/s11606-020-06175-5 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Englander H, Salisbury-Afshar E, Gregg J, Martin M, Snyder H, Weinstein Z, et al. Converging Crises: Caring for Hospitalized Adults With Substance Use Disorder in the Time of COVID-19. J Hosp Med. 2020. October;15(10):628–630. 10.12788/jhm.3485 ; PMCID: PMC7531943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Wallace CL, Wladkowski SP, Gibson A, White P. Grief During the COVID-19 Pandemic: Considerations for Palliative Care Providers. J Pain Symptom Manage. 2020. July;60(1):e70–e76. Epub 2020 Apr 13. 10.1016/j.jpainsymman.2020.04.012 ; PMCID: PMC7153515. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Chua IS, Jackson V, Kamdar M. Webside Manner during the COVID-19 Pandemic: Maintaining Human Connection during Virtual Visits. J Palliat Med. 2020. November;23(11):1507–1509. Epub 2020 Jun 11. 10.1089/jpm.2020.0298 . [DOI] [PubMed] [Google Scholar]
  • 24.Zeh RD, Santry HP, Monsour C, Sumski AA, Bridges JFP, Tsung A, et al. Impact of visitor restriction rules on the postoperative experience of COVID-19 negative patients undergoing surgery. Surgery. 2020. November;168(5):770–776. Epub 2020 Aug 19. 10.1016/j.surg.2020.08.010 ; PMCID: PMC7437486. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.OHSU Fast Facts 2021 [Internet]. Oregon Health and Science University [cited 2021 Jan 26]. Available from: https://www.ohsu.edu/about/ohsu-facts
  • 26.Englander H, Dobbertin K, Lind BK, Nicolaidis C, Graven P, Dorfman C, et al. Inpatient Addiction Medicine Consultation and Post-Hospital Substance Use Disorder Treatment Engagement: a Propensity-Matched Analysis. J Gen Intern Med. 2019. December;34(12):2796–2803. 10.1007/s11606-019-05251-9 ; PMCID: PMC6854181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Collins D, Alla J, Nicolaidis C, Gregg J, Gullickson DJ, Patten A, et al. "If It Wasn’t for Him, I Wouldn’t Have Talked to Them": Qualitative Study of Addiction Peer Mentorship in the Hospital. J Gen Intern Med. 2019. December 12. Epub ahead of print. 10.1007/s11606-019-05311-0 . [DOI] [PubMed] [Google Scholar]
  • 28.Englander H, Collins D, Perry SP, Rabinowitz M, Phoutrides E, Nicolaidis C. "We’ve Learned It’s a Medical Illness, Not a Moral Choice": Qualitative Study of the Effects of a Multicomponent Addiction Intervention on Hospital Providers’ Attitudes and Experiences. J Hosp Med. 2018. November 1;13(11):752–758. Epub 2018 Apr 25. 10.12788/jhm.2993 . [DOI] [PubMed] [Google Scholar]
  • 29.Englander H, Weimer M, Solotaroff R, Nicolaidis C, Chan B, Velez C, et al. Planning and Designing the Improving Addiction Care Team (IMPACT) for Hospitalized Adults with Substance Use Disorder. J Hosp Med. 2017. May;12(5):339–342. 10.12788/jhm.2736 ; PMCID: PMC5542562. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.OHSU Board of Directors Meeting. Portland, Oregon: Oregon Health & Science University; 2020 May 22nd, 2020. Available from: https://www.ohsu.edu/about/board-directors
  • 31.CDC. COVID-19 Case Rate in the US Reported to the CDC, by State/Territory (cases per 100,000). 2020. Available from: https://covid.cdc.gov/covid-data-tracker/#cases_casesper100k
  • 32.Cacciola JS, Alterman AI, Dephilippis D, Drapkin ML, Valadez C Jr, Fala NC, et al. Development and initial evaluation of the Brief Addiction Monitor (BAM). J Subst Abuse Treat. 2013. March;44(3):256–63. Epub 2012 Aug 14. 10.1016/j.jsat.2012.07.013 ; PMCID: PMC3602977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Cameron AY, Shea MT, Randall AB. Acute Shame Predicts Urges for Suicide but not for Substance Use in a Veteran Population. Suicide Life Threat Behav. 2020;50(1):292–9. 10.1111/sltb.12588 [DOI] [PubMed] [Google Scholar]
  • 34.Stockin M, Wandner L, Kurihara C, Spevak C, Griffith S. (150) Short-Term Outcomes following an Intensive Outpatient Program for Patients with Comorbid Substance Use Disorder and Chronic Pain at Walter Reed National Military Medical Center (WRNMMC). The Journal of Pain. 2019;20(4, Supplement):S14. [Google Scholar]
  • 35.Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology. 2006;3(2):77–101. 10.1191/1478088706qp063oa [DOI] [Google Scholar]
  • 36.Clarke V, Braun V. Teaching thematic analysis: Overcoming challenges and developing strategies for effective learning. The Psychologist. 2013;26:120–123. [Google Scholar]
  • 37.Dedoose Version 7.0.23, web application for managing, analyzing, and presenting qualitative and mixed method research data (2018). Los Angeles, CA: SocioCultural Research Consultants, LLC; www.dedoose.com. [Google Scholar]
  • 38.StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC. [Google Scholar]
  • 39.Gupta VK, Hansen H, Mendoza S, Chen XL, Swift RG. Merging Outpatient Addiction and Opioid-Maintenance Programs During A Disaster: Lessons From Hurricane Sandy. Disaster Med Public Health Prep. 2017. October;11(5):531–537. Epub 2017 Mar 7. 10.1017/dmp.2016.190 ; PMCID: PMC6003775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Pouget ER, Sandoval M, Nikolopoulos GK, Friedman SR. Immediate Impact of Hurricane Sandy on People Who Inject Drugs in New York City. Subst Use Misuse. 2015;50(7):878–84. Epub 2015 Mar 16. 10.3109/10826084.2015.978675 ; PMCID: PMC4498981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Tofighi B, Grossman E, Williams AR, Biary R, Rotrosen J, Lee JD. Outcomes among buprenorphine-naloxone primary care patients after Hurricane Sandy. Addict Sci Clin Pract. 2014. January 27;9(1):3. 10.1186/1940-0640-9-3 ; PMCID: PMC3940298. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Mainstreaming Marginalized Groups and Their Capacities. In: Gaillard JC. People’s Response to Disasters in the Philippines. New York: Palgrave Macmillan; 2015. [Google Scholar]
  • 43.Clark-Ginsberg A. A Complexity Approach for Reducing Disaster Risks for Marginalized Urban Populations. Singapore: Springer; 2020. 10.1007/978-981-15-4948-9_10 [DOI] [Google Scholar]
  • 44.Kammerbauer M, Wamsler C. Social inequality and marginalization in post-disaster recovery: Challenging the consensus? International Journal of Disaster Risk Reduction. 2016;24:411–8. 10.1016/j.ijdrr.2017.06.019. [DOI] [Google Scholar]
  • 45.Maxwell JC, Podus D, Walsh D. Lessons learned from the deadly sisters: drug and alcohol treatment disruption, and consequences from Hurricanes Katrina and Rita. Subst Use Misuse. 2009;44(12):1681–94. 10.3109/10826080902962011 . [DOI] [PubMed] [Google Scholar]
  • 46.Kangovi S, Barg FK, Carter T, Levy K, Sellman J, Long JA, et al. Challenges faced by patients with low socioeconomic status during the post-hospital transition. J Gen Intern Med. 2014. February;29(2):283–9. Epub 2013 Aug 6. 10.1007/s11606-013-2571-5 ; PMCID: PMC3912302. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Kansagara D, Ramsay RS, Labby D, Saha S. Post-discharge intervention in vulnerable, chronically ill patients. J Hosp Med. 2012. February;7(2):124–30. Epub 2011 Nov 15. 10.1002/jhm.941 . [DOI] [PubMed] [Google Scholar]
  • 48.Baah FO, Teitelman AM, Riegel B. Marginalization: Conceptualizing patient vulnerabilities in the framework of social determinants of health-An integrative review. Nurs Inq. 2019. January;26(1):e12268. Epub 2018 Nov 29. 10.1111/nin.12268 ; PMCID: PMC6342665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.WHO. Guide to Starting and Managing Needle and Syringe Programmes. Geneva: WHO; 2007. [Google Scholar]
  • 50.The Coronavirus Pandemic Disrupts Opioid Addiction Treatments in Philadelphia. NPR/WAMU. 2020 May 11, 2020.
  • 51.Yehia BR, Winegar A, Fogel R, et al. Association of Race With Mortality Among Patients Hospitalized With Coronavirus Disease 2019 (COVID-19) at 92 US Hospitals. JAMA Netw Open. 2020;3(8):e2018039. 10.1001/jamanetworkopen.2020.18039 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Khatri UG, Pizzicato LN, Viner K, Bobyock E, Sun M, Meisel ZF, et al. Racial/Ethnic Disparities in Unintentional Fatal and Nonfatal Emergency Medical Services-Attended Opioid Overdoses During the COVID-19 Pandemic in Philadelphia. JAMA Netw Open. 2021. January 4;4(1):e2034878. 10.1001/jamanetworkopen.2020.34878 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Zhai Y. A Call for Addressing Barriers to Telemedicine: Health Disparities during the COVID-19 Pandemic. Psychother Psychosom. 2021;90(1):64–66. Epub 2020 Jun 4. 10.1159/000509000 ; PMCID: PMC7316653. [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Cynthia Sieck

31 Dec 2020

PONE-D-20-30950

Understanding the impact of the SARS-COV-2 pandemic on hospitalized patients with substance use disorder

PLOS ONE

Dear Dr. King,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Required changes:

1.  Deeper discussion in the introduction related to the impact of the pandemic and mitigation strategies on PSUD.

2. More detail in the Methods about the hospital population, representativeness of study participants, recruitment process and reasons for non-participation.

3. Reviewer 2 requests several definitions/clarifications of terms.

4.  Strengthening the literature review particularly surrounding issues of phone/internet access among this population and the challenges of utilizing telehealth.

5.  Attention to formatting of references. 

Recommended:

1.  Expanding the discussion of limitations and address the limitation of lack of a telephone may have had on recruiting patients.

2.  Reviewer 1 asks about how the timing of the pandemic may have influenced or shifted themes.  It may be challenging to disentangle timing of interviews with timing of COVID-related changes however more discussion of how the pace of COVID-related changes on data collection and patient perspectives is warranted.

Please submit your revised manuscript by Feb 14 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Cynthia Sieck

Academic Editor

PLOS ONE

Additional Editor Comments:

This manuscript examines the experiences of people with substance use disorder during the COVID-19 pandemic and is a very timely and important issue to understand. The reviewer comments suggest important revisions which would improve the manuscript. Particularly:

1. More detail is needed in the methods section regarding the hospital population and how representative study participants are.

2. More detail is needed about recruitment as discussed by the reviewers.

3. A deeper discussion of how the pandemic itself as well as mitigation strategies related to the pandemic can impact the lives of PSUD would be beneficial. This would provide better context for the challenges this population faces.

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In the Methods, please discuss whether and how the questionnaire was validated and pre-tested. If these did not occur, please provide the rationale for not doing so.

3. Thank you for stating the following in the Acknowledgments Section of your manuscript:

"IMPACT is funded by Oregon Health & Science University and CareOregon.

CK and HE were supported by grants from the National Institutes of Health, National Institute

on Drug Abuse (UG1DA015815/ R01DA037441). This publication was also made possible with

support from the Oregon Clinical and Translational Research Institute (OCTRI), grant number

UL1TR002369 from the National Center for Research Resources (NCRR), a component of the

National Institutes of Health (NIH), and NIH Roadmap for Medical Research."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"CK and HE were supported by grants from the National Institutes of Health, National Institute on Drug Abuse (UG1DA015815/ R01DA037441). This publication was also made possible with support from the Oregon Clinical and Translational Research Institute (OCTRI), grant number UL1TR002369 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. We noted in your submission details that a portion of your manuscript may have been presented or published elsewhere.

"Preliminary results from this work were published virtually at AMERSA in Fall 2020. "

Please clarify whether this publication was peer-reviewed and formally published. If this work was previously peer-reviewed and published, in the cover letter please provide the reason that this work does not constitute dual publication and should be included in the current manuscript.

5. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: N/A

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This manuscript describes findings from a prospective qualitative study of 27 individuals with substance use disorder who were hospitalized during the COVID pandemic in an academic medical center in Portland, Oregon. What is challenging about the manuscript is that because only hospitalized patients with substance use disorder (PSUD) were interviewed, it is difficult to determine the extent to which the COVID-19 impacts describe in the paper are unique to this population or whether other patients in the hospital faced similar challenges. If this facility is a safety net hospital, many of the challenges around housing and other determinants of health in the context of the pandemic may not be all that different for other populations of patients. This limitation is not discussed in the paper.

Introduction: The Introduction clearly and succinctly lays out the key issues that people with substance use disorders (PSUD) face in engaging with the healthcare system. The authors also note the rapid shifts in protocols within hospitals in response to the SARS-COV-2 pandemic. Attention to two issues in the Introduction would strengthen this section. First, the authors contend (page 3), “The SARS-COV-2 pandemic and mitigation strategies may have uniquely impacted people with acute illness and SUD.” This may indeed be the case but 1-2 more sentences about these unique impacts would orient the reader to the authors’ line of reasoning. At the same time, the authors cannot actually provide evidence to support this claim because the study only includes hospitalized PSUD. Second, the statement, “As we assess the ways in which hospitals’ responses to the pandemic have succeeded and failed, we must include voices of people at the margins, and specifically, voices of people with SUD,” should also be explained further. For readers who may be less well-versed in, for example, community-engaged research, further articulating what can be gained by examining the perspectives of PSUD in designing healthcare systems and processes would strengthen the rationale for the research.

Methods, Setting and Study Design: If the authors provided 1-2 more sentences about the broader hospital and the patients typically served, it would better contextualize the findings.

In addition, it was somewhat difficult to tie together the state of SARS-COV-2 changes in the hospital during the specific timeframe of data collection. It appears that, to some degree, processes were stabilizing during the timeframe, but if the paragraph about SARS-COV-2 was woven into the description of when data were collected, it would be more clear.

Also were the measures of accessing healthcare from an existing measure or developed specifically for this study?

Methods, Participants and Data Collection: Adding one sentence that describes the training of the interviewing team is also warranted. Also, consider moving the information about the sample size to this paragraph rather than including as the first sentence in the Results section.

Results: The main findings are clearly conveyed, with themes supported by representative quotations from the interview transcripts. The findings about the challenges for individuals without cell phones are a major theme, but this reviewer wondered how individuals with phones perceived the shift to telehealth. In several sections of the Results, more explicit comparisons of themes for those with (51% of the sample) and those without phones (49%) would be beneficial, as it is difficult to gauge the perspectives of the half of the sample who did have phones.

Discussion: The Discussion does a nice job linking the findings to some of the literature on natural disasters and pandemics. Some of the tone about policy-makers is a bit beyond scope of the data (e.g., “Within Oregon, local, state, and national policy-makers implemented strategies meant to curb the spread of SARS-COV-2 for the masses, but instead inadvertently threatened the survival of people living at the margins”).

A second consideration is if or how themes perhaps shifted over the time period of data collection. Over the 6 weeks of data collection, it seems that the hospital restrictions loosened to some degree (based on the description in Methods about the impact of the pandemic within the hospital), but this is not discussed in terms of the findings.

The Limitations are a bit perfunctory regarding the limitation of focusing on an academic medical center. An additional sentence that elucidates why that is a limitation would be beneficial. Also, given a rapid escalation in cases this fall in Oregon, perhaps a sentence about how timing may affect the findings is warranted.

The discussion about marginalized populations and telemedicine (page 15) would benefit from additional citations, as there have been concerns raised about unequal access to telemedicine both for SUD specifically but also for other health conditions.

References: The Reference list needs careful editing. There is variability in article titles in how the titles are capitalized, some author names seem erroneous (especially #24 and #37), there are inconsistencies in whether journal names are abbreviated or not, and some references pre-2020 lack volume and page numbers.

Reviewer #2: Thank you for inviting me to review this interesting and important paper. It presents the results from a qualitative study conducted with 27 patients hospitalized with substance use disorder during the initial phase of the COVID-19 pandemic in Spring 2020. The objective is clearly stated and appears to have been met (“evaluate how the SARSCOV-2 pandemic altered the experience of healthcare, acute illness, and care transitions among hospitalized patients with substance use disorder.”) The paper is well written and the findings are useful for informing improvements in clinical care for patients with SUD in pandemic settings and beyond. I especially appreciate the careful analysis, inclusion of patients’ voices, and discussion of important implications. I have one overall comment about the literature review and then some minor suggestions about ways that this paper could potentially be improved:

The literature review feels a bit thin in places. Although COVID-19 is newly-emerged infectious disease, there may be experiences from other disasters that could be cited in the Introduction (some is cited in the Discussion section but that feels a bit late – this context would be helpful up front). There are also new studies and commentaries emerging that make me wonder if the lit review could be updated a bit? For example, PMC7419278 discusses some innovations implemented in one clinical setting during the pandemic with implications for care of patients with SUD. Similarly there are a few specific topics (e.g., stigma in the Introduction) where additional recent qualitative studies could be cited (PMID: 30884432). Taken together, these studies underscore the implications of the findings of the present study that if care is not improved for patients with SUD during pandemics (in part by reducing stigma and mistreatment), individuals may leave the hospital against medical advice, which has implications for their own health and others’ (esp. given the infectious nature of COVID). So strengthening the lit review throughout would help.

Minor comments:

Introduction:

Topics like “hospital-based social control” warrant some defining and explaining (as this, in particular, is a relevant issue for this population). Take care throughout to avoid the use of jargon or other terms that a general audience of this journal may not be familiar with.

Methods:

It is unclear what a “prospective qualitative study” is. (also in the Abstract). If participants were enrolled sequentially that is fine but does make this “prospective” in the sense that it was a cohort or other type of study looking forward. And it does not sound like patients were interviewed more than once.

Please explain why there weren’t more efforts to implement telemedicine for this population initially. Experiences from other settings have shown that hospitals can provide wifi enabled devices to inpatients for consults (and even extending to after discharge).

It sounds like data collection was collected remotely but that is not specifically explained. Nor are the recruitment or consent/enrollment processes if this was all remote/virtual. Please explain these procedures and comment on any related challenges or facilitators as this could be informative to the research community.

Similarly, please include more details on IRB review and consent given that there was an unprecedented shift in research operations and oversight during this time period.

What does “at a semantic level” mean? This should be defined in the text.

Results: what were the reasons for declining participation or ineligibility?

Discussion: see earlier comment about moving some of the literature on disasters to the Introduction. This is optional but I feel would help to set the stage earlier on.

Limitations: there is increasing evidence that Black and Hispanic individuals are at higher risk of experiencing opioid-related harms, not just COVID.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Hannah Knudsen

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Feb 26;16(2):e0247951. doi: 10.1371/journal.pone.0247951.r002

Author response to Decision Letter 0


29 Jan 2021

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Thank you. We have updated formatting to PLoS One Style throughout.

2. In the Methods, please discuss whether and how the questionnaire was validated and pre-tested. If these did not occur, please provide the rationale for not doing so.

For the quantitative survey, we included 9 demographics questions (assessing gender, race, ethnicity, housing status, income, education, zip code, cell-phone ownership, and marital status) and 10 questions from the Brief Addiction Monitor. The Brief Addiction Monitor has previously been used in inpatient settings with patients with substance use disorders. Finally, we asked patients about their readiness-to-change by substance, using four questions our team uses to assess substance use (Question: Please describe how you feel about your alcohol/opioid/amphetamine or methamphetamine/other drug use right now: 1) I do not want to think about cutting back or quitting, 2) I want to cut back but I am not ready to quit, 3) I want to quit, and 4) I quit before I was admitted to the hospital). We developed the last question because we have been unable to find a measure that adequately measures readiness to change, by substance, for patients hospitalized with substance use disorders. We piloted tested the full survey among research team members prior to the start of the research project. We have updated our text to include the following:

“For the quantitative survey, we included nine demographics questions and ten questions from the Brief Addiction Monitor (32). The Brief Addiction Monitor has previously been used in inpatient settings with patients with substance use disorders (33, 34). We also assessed participant readiness-to-change by substance, using four questions our team uses in research to assess substance use (“Please describe how you feel about your alcohol/opioid/amphetamine or methamphetamine/other drug use right now: 1) I do not want to think about cutting back or quitting, 2) I want to cut back but I am not ready to quit, 3) I want to quit, and 4) I quit before I was admitted to the hospital”). We developed the last question because we have been unable to find a measure that adequately measures readiness to change, by substance, for patients hospitalized with substance use disorders. We piloted tested the full survey among research team members prior to the start of the research project.” (Page 5, paragraph 3)

3. Thank you for stating the following in the Acknowledgments Section of your manuscript:

"IMPACT is funded by Oregon Health & Science University and CareOregon.

CK and HE were supported by grants from the National Institutes of Health, National Institute

on Drug Abuse (UG1DA015815/ R01DA037441). This publication was also made possible with

support from the Oregon Clinical and Translational Research Institute (OCTRI), grant number

UL1TR002369 from the National Center for Research Resources (NCRR), a component of the

National Institutes of Health (NIH), and NIH Roadmap for Medical Research."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

"CK and HE were supported by grants from the National Institutes of Health, National Institute on Drug Abuse (UG1DA015815/ R01DA037441). This publication was also made possible with support from the Oregon Clinical and Translational Research Institute (OCTRI), grant number UL1TR002369 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Thank you. We have removed funding information from the manuscript, and have included our finalized funding statement in our cover letter.

4. We noted in your submission details that a portion of your manuscript may have been presented or published elsewhere. "Preliminary results from this work were published virtually at AMERSA in Fall 2020." Please clarify whether this publication was peer-reviewed and formally published. If this work was previously peer-reviewed and published, in the cover letter please provide the reason that this work does not constitute dual publication and should be included in the current manuscript.

We apologize for the confusing language- preliminary results from this work were presented in abstract form at AMERSA in Fall 2020. The content of this manuscript was not peer-reviewed nor published, other than a previous version of the abstract only for the conference. We have updated the manuscript to clarify this (Page 19, Prior Presentations).

5. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

Thank you. We are unable to share data because data are potentially identifying and contain sensitive patient information. These restrictions are imposed by our ethics committee. We have updated our cover letter to reflect this, and to provide the contact information for our ethics committee as requested.

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Thank you. We have updated our Supporting Information files per PLoS One guidelines.

5. Review Comments to the Author

Reviewer #1: This manuscript describes findings from a prospective qualitative study of 27 individuals with substance use disorder who were hospitalized during the COVID pandemic in an academic medical center in Portland, Oregon. What is challenging about the manuscript is that because only hospitalized patients with substance use disorder (PSUD) were interviewed, it is difficult to determine the extent to which the COVID-19 impacts describe in the paper are unique to this population or whether other patients in the hospital faced similar challenges. If this facility is a safety net hospital, many of the challenges around housing and other determinants of health in the context of the pandemic may not be all that different for other populations of patients. This limitation is not discussed in the paper.

Thank you for this important comment. Our team cares for patients hospitalized with substance use disorders. It is likely that other patients in the hospital who are marginalized, including patients who are homeless or unemployed but without substance use disorder, do face some similar challenges. One goal of this paper was to illuminate systems-level challenges for one group of highly marginalized patients. If care systems could reframe to address barriers to care for these patients, other patients may benefit as well. A key limitation is that we do not encompass challenges that other patients who experience marginalization in other ways, but who do not have substance use disorders, may face. We have updated to include this in our limitations (Page 16, paragraph 1), and it reads as follows:

“Fourth, it is possible that our research does not encompass all challenges faced by marginalized patients in healthcare systems. While we focus specifically on patients with substance use disorders and highlight that addressing challenges for these patients may benefit other marginalized groups, there may be other, unique, challenges that should be explored through further research with other marginalized patient populations.”

Introduction: The Introduction clearly and succinctly lays out the key issues that people with substance use disorders (PSUD) face in engaging with the healthcare system. The authors also note the rapid shifts in protocols within hospitals in response to the SARS-COV-2 pandemic. Attention to two issues in the Introduction would strengthen this section. First, the authors contend (page 3), “The SARS-COV-2 pandemic and mitigation strategies may have uniquely impacted people with acute illness and SUD.” This may indeed be the case but 1-2 more sentences about these unique impacts would orient the reader to the authors’ line of reasoning. At the same time, the authors cannot actually provide evidence to support this claim because the study only includes hospitalized PSUD.

Thank you. We have updated them manuscript to read as follows (Page 3, paragraph 2):

“Negative and stigmatizing experiences during hospitalization can lead patients with SUDs to avoid presenting to the hospital until illnesses are dire, leave the hospital against medical advice, and trust healthcare providers less than patients without SUDs (15-18). Avoiding healthcare systems, or leaving the hospital without completing recommended therapy, carries increased risk during a pandemic (19). However, hospitals are also in a unique position to support patients with SUD, by providing evidence-based, compassionate care, including harm reduction tools, and by improving systems to meet the needs of people with SUD (20, 21).”

Second, the statement, “As we assess the ways in which hospitals’ responses to the pandemic have succeeded and failed, we must include voices of people at the margins, and specifically, voices of people with SUD,” should also be explained further. For readers who may be less well-versed in, for example, community-engaged research, further articulating what can be gained by examining the perspectives of PSUD in designing healthcare systems and processes would strengthen the rationale for the research.

Thank you for this comment. We have updated our introduction to include, after the sentence you’ve noted, the following:

“For example, by conducting qualitative research directly with people who are marginalized, we can understand how hospital policy changes have impacted them, which can help healthcare systems learn how to better care for patients in the future.” (Page 3 paragraph 1).

Methods, Setting and Study Design: If the authors provided 1-2 more sentences about the broader hospital and the patients typically served, it would better contextualize the findings.

Thank you. We have updated the. First paragraph Setting and Study Design sections to read as follows:

“We performed a prospective qualitative study at an urban academic medical center in Portland, Oregon. This hospital is a 576-bed Level 1 Trauma Center located on the top of a hill in the city [23]. OHSU sees a wide variety of patients for acute medical and surgical illness, and often receives transfers of patients from smaller hospitals across Oregon. In this study, all participants saw an inpatient addiction medicine consult service called the Improving Addiction Care Team (IMPACT). IMPACT is the only inpatient addiction medicine consult service in the state of Oregon, though some other hospitals provide medication for Opioid Use Disorder in inpatient settings. IMPACT cares for adults with SUD, including but not limited to opioids, alcohol, and methamphetamines. The team includes addiction medicine providers, social workers, and peers with lived experienced in recovery. Earlier work describes IMPACT development, intervention, and outcomes [24-27].”

In addition, it was somewhat difficult to tie together the state of SARS-COV-2 changes in the hospital during the specific timeframe of data collection. It appears that, to some degree, processes were stabilizing during the timeframe, but if the paragraph about SARS-COV-2 was woven into the description of when data were collected, it would be more clear.

Thank you for this helpful suggestion. We have reorganized our methods section to integrate the timeline of hospital-based changes and research (Page 4, paragraph 3).

Also were the measures of accessing healthcare from an existing measure or developed specifically for this study?

We have updated the methods section to note the following:

“Participants first answered close-ended questions about demographics and experiences accessing healthcare. We used questions from the Brief Addiction Monitor [30] to capture recent substance use, patterns of use and recovery, and readiness to quit using substances. All other questions were designed by the research team specifically for this study.” (Page 5, paragraph 2)

Methods, Participants and Data Collection: Adding one sentence that describes the training of the interviewing team is also warranted. Also, consider moving the information about the sample size to this paragraph rather than including as the first sentence in the Results section.

Thank you. We have added the following to the methods (Page 5, paragraph 2):

“The interview team consisted of three medical students, two female and one male, all interested in addiction medicine. Prior to the start of the study, two researchers who are experts in qualitative researcher (CN, HE) reviewed qualitative research steps for conducting interviews with the three medical students (CK, TV, DB), and oversaw the project for its duration. Then, one student with more qualitative experience (TV) conducted a mock interview with a student with less qualitative experience (DB) and gave feedback as to how to elicit rich qualitative data. Each of the three interviewers then did an initial one to two interviews. These interview recordings were transcribed, and the full research team reviewed transcripts and provided feedback on interviewing techniques.”

It is study team preference to include the sample size information in the Results section. If the reviewer feels it is essential to move this to the Methods, we are happy to do so.

Results: The main findings are clearly conveyed, with themes supported by representative quotations from the interview transcripts. The findings about the challenges for individuals without cell phones are a major theme, but this reviewer wondered how individuals with phones perceived the shift to telehealth. In several sections of the Results, more explicit comparisons of themes for those with (51% of the sample) and those without phones (49%) would be beneficial, as it is difficult to gauge the perspectives of the half of the sample who did have phones.

Thank you. We have updated the text to include the following:

“While not having a phone was a unique stress for participants trying to access outpatient services, even participants with phones described challenges accessing care. Some participants who contacted their primary care office for a medical issue felt that in pre-COVID times, their primary care provider would have seen them in-office, but because of the pandemic and because they were very sick, they were sent to the emergency department instead.” (Page 11, paragraph 5)

Discussion: The Discussion does a nice job linking the findings to some of the literature on natural disasters and pandemics. Some of the tone about policy-makers is a bit beyond scope of the data (e.g., “Within Oregon, local, state, and national policy-makers implemented strategies meant to curb the spread of SARS-COV-2 for the masses, but instead inadvertently threatened the survival of people living at the margins”).

Thank you- we have removed this sentence.

A second consideration is if or how themes perhaps shifted over the time period of data collection. Over the 6 weeks of data collection, it seems that the hospital restrictions loosened to some degree (based on the description in Methods about the impact of the pandemic within the hospital), but this is not discussed in terms of the findings.

Though hospital policy changed rapidly over the course of the study, most COVID-related changes (increased PPE, no hospital visitors) were consistent throughout the study period. There was some variability in which providers saw patients in person over the study period, however, this was also implemented differently by different hospital teams. Patients from the earliest enrollment date saw some clinicians in person, and patients near the end of the study had some virtual visits. We did not assess the impact of changing policy over time on study findings. We have updated our limitations to read as follows (Page 17, paragraph 1):

“Fifth, as is common in emergencies, policy within the hospital related to COVID-19 rapidly changed over the study period. We do not know to what degree these rapid changes may have impacted study results.”

The Limitations are a bit perfunctory regarding the limitation of focusing on an academic medical center. An additional sentence that elucidates why that is a limitation would be beneficial. Also, given a rapid escalation in cases this fall in Oregon, perhaps a sentence about how timing may affect the findings is warranted.

We have updated our limitations to read as follows:

“Our study has several limitations. First, we conducted our study at a single, academic medical center, which may limit generalizability, as community-based hospitals may see different challenges among patients with substance use disorders admitted to the hospital. Second, Oregon had relatively low rates of SARS-COV-2 infections during the study period, but this has since changed (31). It is possible that patient experiences and priorities differ depending on community prevalence of SARS-COV-2; however, the strains imposed by shuttered services, hospital policies, and high-risk transitions would likely only be further compounded in settings with high SARS-COV-2 cases (for example, in Philadelphia, where treatment clinics did close (48)). Third, our sample had low racial and ethnic diversity. Because Black, Indigenous, and People of Color disproportionately suffered from death and other complications of SARS-COV-2 (49) and also disproportionately experience opioid-related harms, including during the pandemic (50), future work should explore intersecting vulnerabilities of SUD, hospitalization, and acute crises like pandemics in this population. Fourth, it is possible that our research does not encompass all challenges faced by marginalized patients in healthcare systems. While we focus specifically on patients with substance use disorders and highlight that addressing challenges for these patients may benefit other marginalized groups, there may be other, unique, challenges that should be explored through further research with other marginalized patient populations. Fifth, as is common in emergencies, policy within the hospital related to COVID-19 rapidly changed over the study period. We do not know to what degree these rapid changes may have impacted study results. Sixth, additional research is needed to understand how the SARS-COV-2 pandemic directly impacted substance use access, practices, and use. While we found differences in use practices and access by primary substance, this question is better answered using quantitative data.” (Page 16, Paragraph 2)

The discussion about marginalized populations and telemedicine (page 15) would benefit from additional citations, as there have been concerns raised about unequal access to telemedicine both for SUD specifically but also for other health conditions.

We have updated our discussion section to include the following:

“In our study, nearly half of participants did not own a phone. Healthcare system shifts to telemedicine and virtual recovery supports were suddenly inaccessible to patients in need. Globally, shifts to telemedicine have impacted not only patients with substance use disorders, but also patients who are older, with disabilities, with lower socioeconomic status, and who are homeless [49].” (Page 17, paragraph 1)

References: The Reference list needs careful editing. There is variability in article titles in how the titles are capitalized, some author names seem erroneous (especially #24 and #37), there are inconsistencies in whether journal names are abbreviated or not, and some references pre-2020 lack volume and page numbers.

Thank you. We have updated our reference list throughout.

Reviewer #2: Thank you for inviting me to review this interesting and important paper. It presents the results from a qualitative study conducted with 27 patients hospitalized with substance use disorder during the initial phase of the COVID-19 pandemic in Spring 2020. The objective is clearly stated and appears to have been met (“evaluate how the SARSCOV-2 pandemic altered the experience of healthcare, acute illness, and care transitions among hospitalized patients with substance use disorder.”) The paper is well written and the findings are useful for informing improvements in clinical care for patients with SUD in pandemic settings and beyond. I especially appreciate the careful analysis, inclusion of patients’ voices, and discussion of important implications. I have one overall comment about the literature review and then some minor suggestions about ways that this paper could potentially be improved.

Thank you for reviewing our work!

The literature review feels a bit thin in places. Although COVID-19 is newly-emerged infectious disease, there may be experiences from other disasters that could be cited in the Introduction (some is cited in the Discussion section but that feels a bit late – this context would be helpful up front). There are also new studies and commentaries emerging that make me wonder if the lit review could be updated a bit? For example, PMC7419278 discusses some innovations implemented in one clinical setting during the pandemic with implications for care of patients with SUD. Similarly there are a few specific topics (e.g., stigma in the Introduction) where additional recent qualitative studies could be cited (PMID: 30884432). Taken together, these studies underscore the implications of the findings of the present study that if care is not improved for patients with SUD during pandemics (in part by reducing stigma and mistreatment), individuals may leave the hospital against medical advice, which has implications for their own health and others’ (esp. given the infectious nature of COVID). So strengthening the lit review throughout would help.

Thank you for your thoughtful review. We have updated in the second paragraph of the introduction to read as follows, and included both citations you identified (Page 3):

“Hospitalization may be a particularly challenging time for people with SUDs, as they commonly experience untreated withdrawal and pain and work to mitigate hospital-based social control (15). Negative and stigmatizing experiences during hospitalization can lead patients with SUDs to avoid presenting to the hospital until illnesses are dire, leave the hospital against medical advice, and trust healthcare providers less than patients without SUDs (15-18). Avoiding healthcare systems, or leaving the hospital without completing recommended therapy, carries increased risk during a pandemic (19). However, hospitals are also in a unique position to support patients with SUD, by providing evidence-based, compassionate care, including harm reduction tools, and by improving systems to meet the needs of people with SUD (20, 21).”

Minor comments:

Introduction:

Topics like “hospital-based social control” warrant some defining and explaining (as this, in particular, is a relevant issue for this population). Take care throughout to avoid the use of jargon or other terms that a general audience of this journal may not be familiar with.

Thank you. We have updated the introduction to note the following:

“Hospitalization may be a particularly challenging time for people with SUDs, as they commonly experience untreated withdrawal and pain and work to mitigate hospital-based social control (e.g. the rules and regulations that dictate acceptable behavior in hospitals).”

Methods:

It is unclear what a “prospective qualitative study” is. (also in the Abstract). If participants were enrolled sequentially that is fine but does make this “prospective” in the sense that it was a cohort or other type of study looking forward. And it does not sound like patients were interviewed more than once.

We agree- the word prospective is confusing. We have removed this term. (Page 4, paragraph 2).

Please explain why there weren’t more efforts to implement telemedicine for this population initially. Experiences from other settings have shown that hospitals can provide wifi enabled devices to inpatients for consults (and even extending to after discharge).

Thank you. We have updated our manuscript to include the following (Page 4, paragraph 3):

“IMPACT leadership tried to secure personal electronic devices (e.g. smartphones, tablets) for patients to support video communication, but issues of cost and competing priorities were barriers and efforts did not come to fruition until after the study window.”

It sounds like data collection was collected remotely but that is not specifically explained. Nor are the

recruitment or consent/enrollment processes if this was all remote/virtual. Please explain these procedures and comment on any related challenges or facilitators as this could be informative to the research community. Similarly, please include more details on IRB review and consent given that there was an unprecedented shift in research operations and oversight during this time period.

We have updated our methods to include the following:

“Our institutional IRB waived the requirement for written consent given the inability to meet patients in person because of university-wide restrictions, and because of the minimal risk associated with our study. To recruit patients, we called the rooms of hospitalized patients with SUDs who were referred to IMPACT. We ascertained patient interest in learning about the study, and verbally consented patients to participate. Patients were offered $25 gift cards to thank them for participating.” (Page 5, paragraph 2)

What does “at a semantic level” mean? This should be defined in the text.

We have updated the text to include the following:

“We conducted a thematic analysis, using an inductive approach, at a semantic level (e.g. where interview data were taken at face value) (33, 34).” (Page 6, paragraph 4)

Results: what were the reasons for declining participation or ineligibility?

We have updated the text to include the following:

“We approached 42 patients via telephone to participate, and enrolled 27 participants. Of the 15 patients who declined to enroll, 8 said that they were not interested, 2 were managing acute illness and did not want to be on the phone, and 5 did not provide a reason for not participating.” (Page 6, paragraph. 5)

Discussion: see earlier comment about moving some of the literature on disasters to the Introduction. This is optional but I feel would help to set the stage earlier on.

Thank you. In early drafts of this manuscript, the introduction included literature on disasters. After iterative review from our research team, we felt that this was out of place in the introduction, and moved this information to the discussion section. Our sense is that reorganizing to include in the intro again may still feel out of place. However, if the reviewer feels strongly we should reorganize to describe the disaster literature in the introduction, we are happy to do so.

Limitations: there is increasing evidence that Black and Hispanic individuals are at higher risk of experiencing opioid-related harms, not just COVID.

Thank you for this important comment. In the limitations, we have updated to include the following:

“Because Black, Indigenous, and People of Color disproportionately suffered from death and other complications of SARS-COV-2 (49) and also disproportionately experience opioid-related harms, including during the pandemic (50), future work should explore intersecting vulnerabilities of SUD, hospitalization, and acute crises like pandemics in this population.” (Page 17, paragraph 1)

Attachment

Submitted filename: Response to Reviewers 1.29.docx

Decision Letter 1

Cynthia Sieck

17 Feb 2021

Understanding the impact of the SARS-COV-2 pandemic on hospitalized patients with substance use disorder

PONE-D-20-30950R1

Dear Dr. King,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Cynthia Sieck

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Cynthia Sieck

19 Feb 2021

PONE-D-20-30950R1

Understanding the impact of the SARS-COV-2 pandemic on hospitalized patients with substance use disorder

Dear Dr. King:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Cynthia Sieck

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File. Participant survey.

    Survey for participants with substance use disorder, hospitalized during the SARS-COV-2 pandemic.

    (PDF)

    S1 Poster

    (PPTX)

    Attachment

    Submitted filename: Response to Reviewers 1.29.docx

    Data Availability Statement

    We are unable to share data because data are potentially identifying and contain sensitive patient information. These restrictions are imposed by our ethics committee. Oregon Health & Science University’s Institutional Review Board can be contacted by emailing irb@ohsu.edu, or emailing Kathryn Schuff, Program Manager, at schuffk@ohsu.edu.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES